samedan logo

 
 
spacer
home > ebr > winter 2003 > cordia-europabio convention 2003
PUBLICATIONS
European Biopharmaceutical Review

CORDIA-EuropaBio Convention 2003

Europe's first true biotechnology convention got off the ground in style in Vienna during the first week of December 2003. Approximately 1,300 delegates from 37 countries attended the Convention, which featured six plenary sessions, 60 conference panel sessions (across health care, industrial and agri-food biotechnology), six workshops, 10 different therapeutic/technology partnering sessions and an international exhibition with a range of companies from across the world.

The conference programme launched directly into the key issues that the European sector faces with the Opening Plenary featuring representation from all stakeholders in the future development of the European biotechnology industry - political, scientific, patient, mainstream industry and SMEs. The EU's Lisbon Summit objective to become the leading knowledge-based economy by 2010 is clearly not realisable on present performance. Even worse, the gap between Europe and North America is widening with Mrs Mary Harney, Deputy Prime Minister of Ireland and incoming President of the EU Competitiveness Council quoting that whilst the US is currently on average "30 per cent richer than Europe", it will be "50 per cent richer by the year 2050" if things continue as they are.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Review by Dr Helen Abbott, Editor of EBR
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm Expands Relationship With Novan On Formulation Science

MedPharm Ltd, a leader in topical and transdermal drug delivery, has expanded its relationship with the NASDAQ listed biopharmaceutical company Novan Inc. MedPharm has previously supported Novan by testing the company’s unique formulations using its proprietary in vitro models to optimise Novan’s formulations and de-risk product development.
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drug’s manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

23-26 March 2020, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 23 – 26 March 2020. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement